Although the therapeutic role of other cytokines, such as IL-1β and NF-κβ, is controversial, some studies observed that IL-1β, prostaglandin E2 (PGE2), and NF-κβ signaling allowed inhibition of SIRS and treatment of experimental SAP [13–16]. Here, NFKB1 is linked to systemic inflammatory response syndrome.